Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. - Wikidata - wikimedia - TriplyDB

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

http://www.wikidata.org/entity/Q34496969

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Trastuzumab containing regimens for early breast cancer Taxanes for adjuvant treatment of early breast cancer High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller Tamoxifen: catalyst for the change to targeted therapy Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Adjuvant systemic therapy in older women with breast cancer Infracentimetric HER-2 positive breast tumours-review of the literature Biological markers of invasive breast cancer Progress in adjuvant chemotherapy for breast cancer: an overview Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Twenty years of anti-HER2 therapy-associated cardiotoxicity Treatment of early-stage HER2+ breast cancer-an evolving field ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data HER2 testing: a review of detection methodologies and their clinical performance Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.Strategies for modern biomarker and drug development in oncology.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection.Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World.The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

P2860

Q21284978-373710E0-583B-45CE-93DD-6354352F5788 Q24200192-687BB635-9C53-42B7-A86E-ACBCCB95A57D Q24242987-7ED227F7-723F-4F28-83CF-0FBECB2E16FF Q24641848-710D45D6-3375-473F-BAF6-AE66C65EE6F2 Q24652988-5743D407-761A-47ED-94CE-AE763A3CF488 Q24657145-072C6DCB-05AD-477C-8345-121B8C3AB874 Q26741523-92114AFC-ECA2-401F-8474-6DF224D63E4D Q26774597-75E7C2A7-8EDD-4C5D-9A46-93F954D36157 Q26781177-C8D646F0-108C-4366-878E-BCBE9E21D234 Q26798078-FD8AF4F3-F396-4F36-A326-9B5CB673595F Q27001729-CEE43F9F-1E0E-483C-9A80-E7F9ABA1B4A9 Q27006811-701D2279-0936-4EF1-9A43-024CE9EEDD61 Q27025860-92698506-D7F4-4884-B9D6-A1682925EFC9 Q27025863-A6EDD959-D445-42CE-8584-4E5A1901A3D2 Q27851705-194DA134-EA7B-4111-A8A0-9F4CDECE56F3 Q28079391-9CED7BF5-335F-41FA-BA0B-A7C18F4F3F59 Q28081124-24C795CE-4DB5-4771-9798-265D9D7BCEB1 Q28084565-51D3A18C-612F-4240-9B35-7C6364C2D80D Q28240692-FD1D70F0-985B-44E0-9416-F1D6F857742B Q28247338-73D839DE-8B2D-46DD-9D03-96775C2AD9D5 Q28280488-0C396130-02CB-408B-95BA-FE1ECC6AA3E8 Q28477739-5A848DAB-5B35-4E04-8126-4DB25BAD7ADC Q28481420-62C49BA0-7614-41DE-AC04-6FA26600EFF7 Q28547354-9919F42B-6189-4B2C-9C26-3232652E222B Q30249335-024FD48E-E5A1-4E21-A62A-16109835AB7B Q30371966-2D6F231A-D15F-4986-80F7-1A446E74B047 Q30540615-0097FB0B-6147-4AB2-AB13-2F6270B08746 Q30590270-B6448D58-29E0-4172-B8DC-26DF3D8F7460 Q30758991-52CF46DD-194F-46EE-BB3F-999C9FE2361F Q33289240-F97A57FB-0B12-403E-88F6-67E6EB077152 Q33293618-81C301AB-0946-4FCA-BD84-40EBA79768A4 Q33352155-483A4FC0-E39A-473E-8CBC-D81C376F7374 Q33397620-3D01B6DC-EE54-4727-A6A7-7056F1FE932A Q33411110-FFF676AA-82A8-47C9-BEA8-5D61B38CEA15 Q33427353-459120A1-B20B-445F-9623-C810B9D13239 Q33528162-2D03055A-2650-4088-ABD2-32474B01277B Q33561966-DAB17637-227F-4FB5-A29E-973B30B49C1A Q33574045-6E78C8A0-ACBD-4DAA-89BF-D7896701DF1A Q33583280-79B8A973-3354-42E8-9720-09C08CF2671D Q33595085-DA70F9CD-3D01-4580-A32C-5998171B05CF

P2860

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

http://www.wikidata.org/entity/Q34496969

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@ast

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@en

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@nl

type

label

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@ast

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@en

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@nl

prefLabel

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@ast

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@en

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@nl

P1433

Q34496969-74679422-8F09-4B4F-9722-4B99D2044662

P1476

Q34496969-7A5F265B-7568-4F4F-B855-D5F972B31603

P2093

Q34496969-12615AA8-20F3-4AA1-9F9E-755E1A849C92

Q34496969-2DEB67E1-1F28-47BB-BF76-A95C281AC707

Q34496969-33D7E512-584C-4898-B413-88DC99A737E8

Q34496969-3677351A-E57C-4536-8869-C2A7CED10BCC

Q34496969-382B9B02-3DA2-47C7-8C7B-A69C2D494D8E

Q34496969-3891BEE9-18F6-46DE-95B7-C5EA24A360EC

Q34496969-46E3C5EE-99E4-4DB9-8790-681801B53785

Q34496969-53057A9E-74D8-4F35-AA14-5BA554BDFFA1

Q34496969-568022F6-3512-4573-92B6-D387F9F8BDBB

Q34496969-6FAA8FAF-6E51-406B-A9F8-31CFD99642E4

P304

Q34496969-12C9BC75-821A-4CEC-8091-87A8668BB32D

P31

Q34496969-DF466F38-AC7A-4E0A-A79C-3E5C9BC5B3CA

P356

Q34496969-7A19C5AB-33B0-4400-9BEF-1C2FDFFAE2BF

P407

Q34496969-7593DCDA-C738-429F-A361-B986E9AEC209

P433

Q34496969-783BB22E-20B1-4A78-AF57-C754F470D597

P478

Q34496969-7B14D486-6F2C-4A4E-863D-04686CE402B7

P50

Q34496969-12A2E9A8-4602-48AD-8EA5-43C0305AFD34

Q34496969-5C34AB15-D4B6-4350-8E04-56099A73170A

Q34496969-E84D80AA-E929-4876-ABD8-30C4D3201852

P577

Q34496969-1AB27480-C5BE-4B01-B1FA-4B3CA8BE373F

P698

Q34496969-063F500A-0086-43B4-B6B4-9D041ED1DAB0

P356

P1433

The New England Journal of Medicine

P1476

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@en

P2093

Anna-Stina Jääskeläinen

http://www.w3.org/2001/XMLSchema#string

FinHer Study Investigators

http://www.w3.org/2001/XMLSchema#string

Heikki Joensuu

http://www.w3.org/2001/XMLSchema#string

Inkeri Elomaa

http://www.w3.org/2001/XMLSchema#string

Jaana Kaleva-Kerola

http://www.w3.org/2001/XMLSchema#string

Jorma Isola

http://www.w3.org/2001/XMLSchema#string

Kaisu Johansson

http://www.w3.org/2001/XMLSchema#string

Leena Helle

http://www.w3.org/2001/XMLSchema#string

Maija Tarkkanen

http://www.w3.org/2001/XMLSchema#string

Marjo Pajunen

http://www.w3.org/2001/XMLSchema#string

P304

809-820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA053028

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Akseli Hemminki

Taina Turpeenniemi-Hujanen

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16495393

http://www.w3.org/2001/XMLSchema#string